Survey among experts on the future role of tau‐PET in clinical practice and trials

Abstract BACKGROUND Recent advancements in Alzheimer's disease (AD) biomarker research and clinical trials prompt reflection on the value and consequently appropriate use of tau positron emission tomography (tau‐PET) in the future. METHODS We conducted an online survey among dementia and PET ex...

Full description

Saved in:
Bibliographic Details
Main Authors: Marie R. Vermeiren, Ismael L. Calandri, Wiesje M. van derFlier, Elsmarieke van deGiessen, Rik Ossenkoppele
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Online Access:https://doi.org/10.1002/dad2.70033
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850240211266568192
author Marie R. Vermeiren
Ismael L. Calandri
Wiesje M. van derFlier
Elsmarieke van deGiessen
Rik Ossenkoppele
author_facet Marie R. Vermeiren
Ismael L. Calandri
Wiesje M. van derFlier
Elsmarieke van deGiessen
Rik Ossenkoppele
author_sort Marie R. Vermeiren
collection DOAJ
description Abstract BACKGROUND Recent advancements in Alzheimer's disease (AD) biomarker research and clinical trials prompt reflection on the value and consequently appropriate use of tau positron emission tomography (tau‐PET) in the future. METHODS We conducted an online survey among dementia and PET experts worldwide to investigate the anticipated future role of tau‐PET in clinical practice and trials. RESULTS Two hundred sixty‐eight dementia experts, comprising 143 clinicians and 121 researchers, covering six continents participated. The vast majority (90%) fostered a positive attitude toward the added value of tau‐PET in clinical practice, particularly for staging, diagnosing, monitoring, and prognostication in a cognitively impaired memory clinic population. Experts anticipated an important role for tau‐PET for participant selection (76%–100%) and measuring endpoints (75%–97%), in both anti‐amyloid and anti‐tau drug trials. DISCUSSION Our global survey study shows that dementia experts envision an important role for tau‐PET in the future, both in clinical practice and in drug trials, beyond current guidelines and practices. Highlights Dementia experts envision an important role for tau‐PET in the future. Experts indicate that a tau‐PET scan could influence patient management. Experts anticipate the utility of tau‐PET for participant selection and endpoints in drug trials. There is a gap between the anticipated usefulness of tau‐PET and current clinical practices.
format Article
id doaj-art-4d4967d1b7cd47a5851d1892366de602
institution OA Journals
issn 2352-8729
language English
publishDate 2024-10-01
publisher Wiley
record_format Article
series Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
spelling doaj-art-4d4967d1b7cd47a5851d1892366de6022025-08-20T02:00:55ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292024-10-01164n/an/a10.1002/dad2.70033Survey among experts on the future role of tau‐PET in clinical practice and trialsMarie R. Vermeiren0Ismael L. Calandri1Wiesje M. van derFlier2Elsmarieke van deGiessen3Rik Ossenkoppele4Alzheimer Center Amsterdam, Neurology Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The NetherlandsAlzheimer Center Amsterdam, Neurology Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The NetherlandsAlzheimer Center Amsterdam, Neurology Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The NetherlandsRadiology & Nuclear Medicine Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam The NetherlandsAlzheimer Center Amsterdam, Neurology Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The NetherlandsAbstract BACKGROUND Recent advancements in Alzheimer's disease (AD) biomarker research and clinical trials prompt reflection on the value and consequently appropriate use of tau positron emission tomography (tau‐PET) in the future. METHODS We conducted an online survey among dementia and PET experts worldwide to investigate the anticipated future role of tau‐PET in clinical practice and trials. RESULTS Two hundred sixty‐eight dementia experts, comprising 143 clinicians and 121 researchers, covering six continents participated. The vast majority (90%) fostered a positive attitude toward the added value of tau‐PET in clinical practice, particularly for staging, diagnosing, monitoring, and prognostication in a cognitively impaired memory clinic population. Experts anticipated an important role for tau‐PET for participant selection (76%–100%) and measuring endpoints (75%–97%), in both anti‐amyloid and anti‐tau drug trials. DISCUSSION Our global survey study shows that dementia experts envision an important role for tau‐PET in the future, both in clinical practice and in drug trials, beyond current guidelines and practices. Highlights Dementia experts envision an important role for tau‐PET in the future. Experts indicate that a tau‐PET scan could influence patient management. Experts anticipate the utility of tau‐PET for participant selection and endpoints in drug trials. There is a gap between the anticipated usefulness of tau‐PET and current clinical practices.https://doi.org/10.1002/dad2.70033Alzheimer's diseasepositron emission tomographytautrials
spellingShingle Marie R. Vermeiren
Ismael L. Calandri
Wiesje M. van derFlier
Elsmarieke van deGiessen
Rik Ossenkoppele
Survey among experts on the future role of tau‐PET in clinical practice and trials
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Alzheimer's disease
positron emission tomography
tau
trials
title Survey among experts on the future role of tau‐PET in clinical practice and trials
title_full Survey among experts on the future role of tau‐PET in clinical practice and trials
title_fullStr Survey among experts on the future role of tau‐PET in clinical practice and trials
title_full_unstemmed Survey among experts on the future role of tau‐PET in clinical practice and trials
title_short Survey among experts on the future role of tau‐PET in clinical practice and trials
title_sort survey among experts on the future role of tau pet in clinical practice and trials
topic Alzheimer's disease
positron emission tomography
tau
trials
url https://doi.org/10.1002/dad2.70033
work_keys_str_mv AT mariervermeiren surveyamongexpertsonthefutureroleoftaupetinclinicalpracticeandtrials
AT ismaellcalandri surveyamongexpertsonthefutureroleoftaupetinclinicalpracticeandtrials
AT wiesjemvanderflier surveyamongexpertsonthefutureroleoftaupetinclinicalpracticeandtrials
AT elsmariekevandegiessen surveyamongexpertsonthefutureroleoftaupetinclinicalpracticeandtrials
AT rikossenkoppele surveyamongexpertsonthefutureroleoftaupetinclinicalpracticeandtrials